Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)

9 Jan 2020 10:04

Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN) 09-Jan-2020 / 10:03 GMT/BST


 

London, UK, 9 January 2020

Edison issues initiation on Silence Therapeutics (SLN)

We are initiating coverage of Silence Therapeutics (SLN), a developer of siRNA drugs for diseases that can be genetically targeted. Silence has a proprietary platform for developing siRNA therapeutics, the strength of which was highlighted by preclinical development deals with Mallinckrodt and Takeda (details below). The company will also be re-entering the clinic in Q120 with SLN124, its own drug for iron overload. We are initiating with a valuation of £345m or 440p per share.

 

Our initial valuation of £345m or 440p per share is based on a risk-adjusted NPV analysis of the firm's assets and revenue streams and is driven primarily by our valuation of SLN124 (£141m). We forecast that it will require £105m in additional capital to reach profitability in 2026, offset by potential business development deals.

Click here to view the full report.

 

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway, +1 646 653 7036

healthcare@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

949913 09-Jan-2020 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
24th Apr 20094:35 pmRNSPrice Monitoring Extension
1st Apr 20097:00 amPRNUnaudited Preliminary Results
30th Mar 200912:15 pmPRNNotice of Results
27th Mar 20094:40 pmRNSSecond Price Monitoring Extn
27th Mar 20094:35 pmRNSPrice Monitoring Extension
19th Mar 20091:22 pmPRNHolding(s) in Company
16th Feb 20093:37 pmPRNHolding(s) in Company
21st Jan 20097:00 amPRNStatement re Patent Update
19th Jan 20091:00 pmPRNHolding(s) in Company
15th Jan 20093:00 pmPRNTotal Voting Rights
15th Jan 20099:45 amPRNHolding(s) in Company
13th Jan 20094:36 pmRNSPrice Monitoring Extension
12th Jan 20097:00 amPRNStatement re Change of operating address
9th Jan 200911:20 amPRNStatement re Patent Grant
8th Jan 20092:21 pmPRNResearch Update
8th Jan 200912:03 pmPRNIssue of Equity
5th Jan 20094:40 pmRNSSecond Price Monitoring Extn
5th Jan 20094:35 pmRNSPrice Monitoring Extension
2nd Jan 20094:35 pmRNSPrice Monitoring Extension
31st Dec 200812:40 pmRNSSecond Price Monitoring Extn
31st Dec 200812:36 pmRNSPrice Monitoring Extension
31st Dec 20087:00 amPRNTotal Voting Rights
18th Dec 20084:35 pmRNSPrice Monitoring Extension
12th Dec 20084:40 pmRNSSecond Price Monitoring Extn
12th Dec 20084:36 pmRNSPrice Monitoring Extension
11th Dec 20087:10 amPRNHolding(s) in Company
10th Dec 20087:00 amPRNStatement re Patent Decision
5th Dec 200812:05 pmPRNIssue of Equity
4th Dec 20087:00 amPRNResearch Update
1st Dec 20087:00 amPRNResearch Update
18th Nov 20087:00 amPRNStatement re Patent Issue
13th Nov 20081:00 pmPRNHolding(s) in Company
10th Nov 20084:44 pmRNSSecond Price Monitoring Extn
10th Nov 20084:37 pmRNSPrice Monitoring Extension
29th Oct 200811:00 amPRNHolding(s) in Company
27th Oct 20089:45 amPRNDirector/PDMR Shareholding
22nd Oct 200812:51 pmPRNDirector/PDMR Shareholding
22nd Oct 20087:00 amPRNDirector/PDMR Shareholding
17th Oct 20083:34 pmPRNAGM Statement
8th Oct 200810:15 amPRNHolding(s) in Company
26th Sep 20085:05 pmPRNDirector/PDMR Shareholding
26th Sep 200811:55 amPRNStatement re Intellectual Property
25th Sep 20087:00 amPRNHalf-yearly Report
24th Sep 200811:40 amPRNHolding(s) in Company
29th Aug 200812:15 pmPRNHolding(s) in Company
26th Aug 20085:11 pmPRNHolding(s) in Company
7th Aug 20088:57 amPRNHolding(s) in Company
5th Aug 20082:00 pmPRNHolding(s) in Company
31st Jul 20087:00 amPRNStatement re Notice of Patent Allowance
30th Jul 20084:25 pmPRNStatement re Notice of Patent Allowance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.